Neurological Disorders Evaluation Flashcards

A 52-year-old commercial truck driver presents with a diagnosis of narcolepsy with cataplexy, currently controlled with sodium oxybate and modafinil. He reports no sleep attacks in the past 18 months and brings documentation from his sleep specialist. Under FMCSA medical standards, what is the correct determination?

Answer: He must be disqualified because narcolepsy with cataplexy is an absolute disqualifying condition regardless of treatment status

Narcolepsy with cataplexy is an absolute disqualifying condition under FMCSA regulations (49 CFR 391.41(b)(8)). A driver with this diagnosis cannot be certified regardless of how well it is controlled with medication. The presence of cataplexy — sudden loss of muscle tone — poses an unacceptable safety risk in a CMV operator. There is no exemption program for narcolepsy with cataplexy, unlike some other conditions.

A driver has a well-documented history of a single unprovoked seizure 4 years ago, with no recurrence. He has been off all antiepileptic medications for 3 years and has a normal EEG and MRI. His neurologist provides a letter stating seizure recurrence risk is equivalent to the general population. Which of the following best describes the FMCSA medical examiner's role in this situation?

Answer: The examiner must disqualify the driver because any history of unprovoked seizure is permanently disqualifying under federal standards

Under FMCSA regulations, a driver with a history of epilepsy or seizure disorder — including a single unprovoked seizure — is disqualified from operating a CMV in interstate commerce. The regulation does not provide for reinstatement based on symptom resolution, medication discontinuation, or normalized diagnostic studies. The neurologist's risk opinion, while clinically relevant, does not override the federal categorical standard. Drivers with seizure histories must pursue an exemption through the FMCSA's seizure exemption program, not standard certification.

During a DOT physical, a 47-year-old driver discloses a diagnosis of essential tremor affecting both hands. He states it does not interfere with driving. Physical exam reveals a moderate bilateral postural tremor with no resting component, no rigidity, and intact coordination on finger-nose testing. What is the most appropriate next step?

Answer: Perform a functional assessment or road test to determine whether the tremor impairs safe CMV operation, and certify only if function is preserved

Essential tremor is not a categorically disqualifying condition. FMCSA standards require that a driver be physically qualified to operate a CMV safely — the key question is functional impairment, not diagnosis. When a tremor is present, the examiner must evaluate whether it interferes with the driver's ability to safely operate the vehicle, including grip strength, steering, and fine motor tasks. A functional assessment or skills evaluation (road test) is the appropriate mechanism. If function is unimpaired, certification is appropriate; if impaired, further evaluation or disqualification may be warranted.

A driver presents with a diagnosis of relapsing-remitting multiple sclerosis. He is currently in remission, on natalizumab, and has had no relapse in 22 months. Neurological exam reveals mild left leg spasticity with no gait disturbance and normal upper extremity function. His neurologist supports return to driving. Which factor would most appropriately lead the medical examiner to issue a certification shorter than 2 years?

Answer: The unpredictable relapsing nature of MS, which warrants a shortened certification interval to monitor for functional decline

MS with a relapsing course introduces the risk of unpredictable neurological deterioration, which directly affects driving safety. While this driver is currently functional and stable, the medical examiner is empowered under FMCSA guidance to shorten the certification interval (e.g., to 1 year or 6 months) to ensure more frequent monitoring of neurological status. Natalizumab is not categorically disqualifying; the issue is not the drug itself but the underlying condition's trajectory. Mild spasticity without functional impairment does not constitute loss of limb use. The rationale for a shortened interval is the relapsing-remitting pattern — not any individual finding in isolation.

A 61-year-old interstate bus driver was diagnosed with a cerebral TIA 7 months ago, confirmed by DWI-negative MRI and normal carotid duplex. He is on aspirin and a statin, has normal neurological exam today, and his internist has cleared him for return to work. Under FMCSA standards, what is the most accurate statement regarding his certification status?

Answer: He must wait a minimum of 12 months from the TIA event before being eligible for certification, and must demonstrate full recovery with specialist clearance

Under FMCSA advisory criteria, a driver who has experienced a TIA must be disqualified and should not be certified until at least 12 months after the event, with documentation of full neurological recovery, no subsequent events, and specialist evaluation confirming fitness. The 12-month waiting period accounts for the elevated near-term stroke risk following TIA. Seven months is insufficient, regardless of normal exam or internist clearance. The standard applies to all CMV drivers in interstate commerce; bus operators are not held to a separately codified higher standard in this context under federal DOT medical rules.

A driver with known Parkinson's disease presents for a DOT physical. He is on carbidopa-levodopa with good motor control during the examination and no 'off' episodes in the past 4 months. Neuropsychological testing performed 6 months ago showed mild executive function deficits but intact memory and attention. His movement disorder specialist states he is 'stable.' Which of the following represents the examiner's most defensible certification decision?

Answer: Decline to certify due to the progressive nature of Parkinson's disease combined with documented executive function deficits, and request updated neuropsychological testing before any certification decision

Parkinson's disease is a progressive neurodegenerative condition, and executive function deficits are particularly relevant to CMV safety — they affect hazard anticipation, route planning, and complex decision-making. Neuropsychological testing from 6 months ago showing even mild executive deficits should not be treated as current, especially in a progressive disease. The most defensible action is to defer certification and request current (not 6-month-old) neuropsychological testing before deciding. The specialist's 'stable' endorsement addresses motor symptoms but does not resolve the cognitive concern. A 2-year certificate in this context would be indefensible; issuing any certificate without updated cognitive data is premature given the documented deficit and progressive trajectory.